Sort   by:  
 Page size 
UnknownPhotoactive monofunctional Pt(ii)-cyanine complex for nucleus and mitochondria dual-targeted antitumor therapy.
Not available
S-EPMC12278765 | biostudies-literature
UnknownDual Gene Delivery Reagents From Antiproliferative Alkylphospholipids for Combined Antitumor Therapy.
Not available
S-EPMC7566913 | biostudies-literature
UnknownDarolutamide Potentiates the Antitumor Efficacy of a PSMA-targeted Thorium-227 Conjugate by a Dual Mode of Action in Prostate Cancer Models.
Not available
S-EPMC9401501 | biostudies-literature
UnknownDual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity.
Not available
S-EPMC10201251 | biostudies-literature
UnknownNHS-IL12 and bintrafusp alfa combination therapy enhances antitumor activity in preclinical cancer models.
Not available
S-EPMC8718653 | biostudies-literature
ProteomicsStudy on the mechanism of action of the Pt(IV) complex with lonidamine ligands by ultrafast chemical proteomics
Platinum (II) complexes such as cisplatin among the few others are well-known and approved for clinical use as anticancer metal-based drugs. In spite of their successful and wide acceptance, the respective chemotherapy is associated with severe side effects and the ability of tumors to quickly devel...
ORGANISM(S): Homo sapiens (Human) 
2025-05-26 | PXD058413 | Pride
Dual action antitumor therapy Thermal proteome profiling Mechanism of action Expression proteomics Platinum complexes Ultrafast proteomics 
UnknownCharge and Size Dual Switchable Nanocage for Novel Triple-Interlocked Combination Therapy Pattern.
Not available
S-EPMC7509747 | biostudies-literature
UnknownBioengineered hybrid dual-targeting nanoparticles reprogram the tumour microenvironment for deep glioblastoma photodynamic therapy.
Not available
S-EPMC12361390 | biostudies-literature
ProteomicsAn antibody drug conjugate-like agent DTLL sensitizes gemcitabine-sensitive/resistant pancreatic cancer on basis of SMAD4 profiles
Chemoresistance to gemcitabine limits its clinical implementation for pancreatic ductal adenocarcinoma (PDAC). We previously generated an antibody drug conjugate (ADC) -like agent, EGFR/HER2 dual-targeting ligand-based lidamycin (DTLL), and studied the effect of DTLL combined with gemcitabine and th...
ORGANISM(S): Homo Sapiens 
2022-03-02 | PXD031977 |
GenomicsNuclear receptor ESRRA promotes ERa-positive breast cancer through dual action on super enhancers and promoters to regulate gene transcriptional programs
Nuclear receptor ESRRA promotes ERa-positive breast cancer through dual action on super enhancers and promoters to regulate gene transcriptional programs
PRJNA1112476 | ENA
Sort   by:  
 Page size